Molecular Diagnosis & Therapy

, Volume 16, Issue 5, pp 317–322

Cetuximab

A Guide to Its Use in Combination with FOLFIRI in the First-Line Treatment of Metastatic Colorectal Cancer in the USA

Authors

    • Adis41 Centorian Drive
Adis Drug Clinical Q&A

DOI: 10.1007/s40291-012-0007-2

Cite this article as:
Lyseng-Williamson, K.A. Mol Diagn Ther (2012) 16: 317. doi:10.1007/s40291-012-0007-2

Abstract

Cetuximab (Erbitux®) is a monoclonal antibody that targets the epidermal growth factor receptor (EGFR). In the USA, the approval of cetuximab has been recently expanded to include the first-line treatment of patients with KRAS mutation-negative (wild-type), EGFR-expressing, metastatic colorectal cancer (mCRC) when used in combination with FOLFIRI (irinotecan, fluorouracil, leucovorin [folinic acid]). The addition of cetuximab to first-line treatment with FOLFIRI improved progression-free survival, overall survival, and objective response rates relative to treatment with FOLFIRI alone in patients with EGFR-expressing mCRC with KRAS wild-type tumors. Therefore, cetuximab plus FOLFIRI is a useful biomarker-directed option in the first-line treatment of this patient population.

Copyright information

© Springer International Publishing Switzerland 2012